MNKD - MannKind Corporation - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.282B

Cash

166.1M

Avg Qtr Burn

-15.32M

Short % of Float

15.26%

Insider Ownership

2.36%

Institutional Own.

52.68%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Afrezza® (insulin human) Inhalation Powder Details Diabetes, Type 1 diabetes, Type 2 diabetes	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tyvaso DPI (Treprostinil Technosphere®) (inhaled treprostinil) Details Pulmonary arterial hypertension, Heart disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Afrezza® (insulin human) Inhalation Powder Details Type 1 diabetes, Diabetes, Type 2 diabetes	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Clofazimine inhalation suspension (MNKD 101) Details Nontuberculous mycobacterial lung disease, Lung disease	Phase 2/3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.